Karyopharm Therapeutics Inc.
KPTI
$4.59
-$0.05-1.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.78% | 4.03% | -234.80% | 163.68% | 10.70% |
| Total Depreciation and Amortization | -3.70% | -2.41% | -8.79% | 7.06% | 10.39% |
| Total Amortization of Deferred Charges | 9.16% | -2.08% | 72.30% | 571.63% | -4.15% |
| Total Other Non-Cash Items | -142.12% | -1,864.57% | 99.36% | -1,437.87% | -2.45% |
| Change in Net Operating Assets | -116.21% | -10.22% | 210.61% | 11.58% | -157.00% |
| Cash from Operations | -51.04% | -32.68% | 49.47% | 11.95% | -135.27% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.69% | 97.27% | -85.42% | 131.59% | -17.54% |
| Cash from Investing | 3.32% | 97.98% | -85.42% | 133.65% | -18.27% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -206.44% | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -- | -- |
| Foreign Exchange rate Adjustments | 125.00% | -155.56% | 427.27% | 31.25% | -117.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.83% | 13.31% | -122.23% | 346.41% | -353.18% |